$GBSN (Great Basin Scientific, Inc.)

$GBSN {{ '2016-09-15T10:09:23+0000' | timeago}} • Announcement

The reverse stock split will reduce $GBSN's outstanding common stock from about 78.4MM shares to about 1MM shares. The reverse stock split will affect all holders of company's common stock uniformly, and will not affect any stockholder's percentage ownership interest in the company or proportionate voting power.

$GPP {{ '2017-07-20T21:06:34+0000' | timeago}} • Announcement

$GPP BoD declared a quarterly cash distribution of $0.45 per unit on all of its outstanding common and subordinated units, or $1.80 per unit on an annualized basis, for 2Q17. The distribution is payable on Aug. 11, 2017, to unitholders of record at the close of business on Aug. 4, 2017.

$ABT {{ '2017-07-20T19:55:45+0000' | timeago}} • Webcast

For 3Q17, $ABT expects adjusted EPS of $0.64-0.66, with operational sales growth expected in the mid-single digits. At current exchange rates, the company expects operational sales growth to have a negative YoY impact of around 0.5%.

$ABT {{ '2017-07-20T19:45:56+0000' | timeago}} • Webcast

$ABT said that on a comparable operational basis, 3Q17 Established Pharmaceuticals sales growth is expected in the high double-digit, while in Nutrition, sales growth is expected in low single-digit. In Diagnostics, $ABT expects sales to increase mid-to-high single digits and in Medical Devices, sales is expected to increase double-digits.

$PYPL {{ '2017-07-20T19:23:41+0000' | timeago}} • Announcement

$PYPL announced a partnership with $JPM that will make it easy to add Chase cards via Chase Pay to PayPal accounts, and will soon offer customers the option of paying with Ultimate Rewards points when linked through Chase Pay at $PYPL’s online merchants. $PYPL will also be able to process payments on ChaseNet, a closed-loop payment network.

$ABT {{ '2017-07-20T17:49:19+0000' | timeago}} • Announcement

$ABT raised its full year profit forecast backed by the intention of closing the Alere acquisition in 2017. The company raised its FY17 adjusted earnings from continuing operations guidance by $0.03 to a range of $2.43-2.53 per share. Reported EPS forecast was also raised from the range of $0.92-1.02 to $1.03-1.13, reflecting double-digit growth.

$ABT {{ '2017-07-20T17:36:53+0000' | timeago}} • Announcement

Declining operating earnings and rising costs and expenses hit $ABT 2Q17 earnings as much as 54%. Earnings plunged to $283MM or $0.15 from $615MM or $0.40 per share a year earlier. Sales, however, surged 24.4% on St. Jude Medical acquisition. On an adjusted basis, $ABT reported EPS above its previous guidance range at $0.62 per share.

$PYPL {{ '2017-07-20T15:44:04+0000' | timeago}} • Announcement

Payment services provider $PYPL and $C have expanded their strategic agreement for broadening consumer payment choices. The partnership will allow Citi card-members to use their ThankYou Points to pay for all or part of purchases when shopping online through the PayPal gateway in US. The facility will be launched next year.

$ABT {{ '2017-07-20T12:52:57+0000' | timeago}} • Infographic

$ABT Abbott Laboratories Earnings AlphaGraphic: Q2 2017 Highlights

$BDX {{ '2017-07-19T13:58:34+0000' | timeago}} • Announcement

$BDX received 510(k) clearance from the FDA for the BD FACSLyric flow cytometer system, an easy-to-use in vitro diagnostic (IVD) system, for use with BD Multitest assays for immunological assessment of individuals and patients having or suspected of having immune deficiency.

$GS {{ '2017-07-19T11:22:37+0000' | timeago}} • Webcast

$GS advised a number of important transactions that were announced during 2Q17, including $BCR's $24Bil sale to $BDX. $AMZN's $13.7Bil acquisition of $WFM, and $DFT's $7.6Bil merger with $DLR.

$JNJ {{ '2017-07-18T19:50:54+0000' | timeago}} • Webcast

$JNJ expects that the growth acceleration in the back half of 2017 will create some momentum going into 2018, as the majority of growth acceleration in both Hospital Medical Devices and Consumer have to do with new product launches. However, the company said it is not prepared to talk about guidance.

$JNJ {{ '2017-07-18T19:30:46+0000' | timeago}} • Webcast

$JNJ CEO Alex Gorsky said during the conference call, "We remain very optimistic about Pharma in the second half of the year and we continue to see really strong uptake both with DARZALEX and the various multiple myeloma indications earlier utilization."

$JNJ {{ '2017-07-18T18:58:31+0000' | timeago}} • Webcast

$JNJ said it has a pipeline of more than 10 new blockbuster products to launch or file for regulatory approval in the next five years, each with greater than $1Bil in peak year sales potential.

$V {{ '2017-07-18T15:19:39+0000' | timeago}} • Announcement

To boost digital and mobile payments, $V and $PYPL extended their partnership in Europe as they have done in the US and Asia-Pacific regions. PayPal will use its banking license in Europe to offer Visa accounts. Visa and PayPal already extended their partnership in early April across Asia-Pacific to accelerate digital and mobile payments.

$PYPL {{ '2017-07-18T14:38:26+0000' | timeago}} • Announcement

$PYPL acquired multi-channel bill payment processor TIO Networks Corp. for $2.64 per share in cash or an approx. $238MM equity value. TIO will operate as a separate service within $PYPL under the leadership of Hamed Shahbazi, VP of Bill Pay & General Manager, PayPal Canada Bill Pay Services, reporting to John Kunze, VP of $PYPL.

$JNJ {{ '2017-07-18T11:59:48+0000' | timeago}} • Infographic

$JNJ Johnson & Johnson Earnings AlphaGraphics: Q2 2017 highlights

$JNJ {{ '2017-07-18T11:26:59+0000' | timeago}} • Announcement

Medical Devices segment was the top performer for $JNJ in 2Q17, with a growth of 4.9%. While Consumer segment added to this with a 1.7% growth, Pharmaceutical segment edged down 0.2%.

$JNJ {{ '2017-07-18T11:19:55+0000' | timeago}} • Announcement

$JNJ CEO Alex Gorsky said, "Our pharmaceutical pipeline continued its strong momentum with the approval of TREMFYA as well as the submission and approval of several key line extensions. We are optimistic that the investments we are making will accelerate our sales growth in the second half of this year."

$JNJ {{ '2017-07-18T11:14:25+0000' | timeago}} • Announcement

$JNJ, which recently acquired Actelion Ltd for $30Bil, raised its sales guidance for FY17 to $75.8-76.1Bil. Additionally, the New Brunswick, NJ - based company raised its adjusted earnings guidance for the same period to $7.12-7.22 per share.

$JNJ {{ '2017-07-18T11:08:14+0000' | timeago}} • Announcement

Pharmaceutical giant $JNJ reported growth in sales and adjusted EPS in 2Q17. While sales increased 2% to $18.8Bil riding on International sales growth of 2.3%, adjusted EPS stood at $1.83, representing an increase of 3.1%. On a GAAP basis, net earnings were down to $3.8Bil, or $1.40 per share, compared to $4Bil, or $1.43 per share, a year ago.

Recent Transcripts

JNJ (Johnson & Johnson)
Tuesday, July 18 2017 - 12:30pm
HOLX (Hologic Inc.)
Wednesday, May 10 2017 - 8:30pm
SNAP (Snap Inc.)
Wednesday, May 10 2017 - 8:30pm
ONDK (On Deck Capital, Inc.)
Monday, May 8 2017 - 12:00pm
BDX (Becton, Dickinson and Company)
Thursday, May 4 2017 - 12:00pm
FIT (Fitbit Inc.)
Wednesday, May 3 2017 - 9:00pm
QGEN (Qiagen NV)
Wednesday, May 3 2017 - 1:00pm
GNMK (GenMark Diagnostics, Inc.)
Tuesday, May 2 2017 - 8:30pm
GPP (Green Plains Partners LP)
Tuesday, May 2 2017 - 3:00pm
BDX (Becton, Dickinson and Company)
Tuesday, May 2 2017 - 12:00pm
CC (The Chemours Company)
Tuesday, May 2 2017 - 12:00pm
PYPL (PayPal Holdings, Inc.)
Wednesday, April 26 2017 - 9:00pm
ILMN (Illumina Inc.)
Tuesday, April 25 2017 - 9:00pm
QDEL (Quidel Corp.)
Monday, April 24 2017 - 9:00pm
ABT (Abbott Laboratories)
Wednesday, April 19 2017 - 1:00pm
JNJ (Johnson & Johnson)
Tuesday, April 18 2017 - 12:30pm
GNMK (GenMark Diagnostics, Inc.)
Tuesday, February 28 2017 - 9:30pm
FIT (Fitbit Inc.)
Wednesday, February 22 2017 - 10:00pm
CC (The Chemours Company)
Thursday, February 16 2017 - 1:30pm
ONDK (On Deck Capital, Inc.)
Thursday, February 16 2017 - 1:00pm

AlphaGraphics you may like